Eric Halioua

Eric Halioua

Company: PDC*line Pharma

Job title: President & Chief Executive Officer


Discovering the Optimal Clinical Setting for Achieving Positive & Accurate Clinical Results to Streamline Candidate Approval 3:00 pm

To successfully carry out trials for neoantigen therapies, the field needs to understand what the best clinical setting is and what conditions should be used to get the most accurate and reliable results. This enables neoantigen therapies to be fast-tracked through the clinic in order to get to the patients in need faster. What learnings…Read more

day: Pre-Conference Day

Fireside Chat: Discussing Investment Opportunities for Better Understanding of What Venture Capitalists are Looking for to Enable Advancement of Neoantigen Therapies 12:00 pm

What are the risk factors that investors are concerned about causing them to withold? How to develop the most effective data packages for investors? How do investors view neoantigen companies?Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.